New research out of Harvard University strongly suggests that infection with the Epstein-Barr virus (EBV) is the leading cause of a debilitating disease of the brain and CNS – multiple sclerosis.
If you are not happy with the results below please do another search
50 search results for:
Former U.S. Food and Drug Administration Commissioner Robert Califf is one step closer to returning to his old office after the Senate Health, Education, Labor and Pensions Committee advanced his nomination in a 13–8 bipartisan vote.
The next “giant leap” for humans may be a trip to Mars, but having enough oxygen-carrying red blood cells for the journey might present a challenge, new research suggests.
Affini-T Therapeutics, a new cell therapy company launched by researchers from Fred Hutchinson Cancer Center, made its public debut at the 2022 J.P. Morgan Healthcare Conference with a mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
The World Health Organization updated WHO’s treatment guidelines for COVID-19 for the eighth time, recommending baricitinib for individuals with severe COVID-19 when used with corticosteroids. In other news, researchers from the Medical University of Bialystok in Poland identified a gene that appears to double the risk of severe COVID-19.
A safety panel of the European drug regulator on January 14 recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca’s COVID-19 vaccine.
A Johnson and Johnson COVID-19 vaccine booster shot is 85 percent effective in protecting against being hospitalized by the Omicron variant for 1-2 months after the shot is received, the head of South Africa’s Medical Research Council (SAMRC) said on January 14.
The U.S. health regulator on January 13 approved Zoetis Inc,’s once-a-month injection to treat pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints in older cats.
Scorpion Therapeutics and AstraZeneca partnered to develop precision medicines against previously hard-to-target cancer proteins.
Since acquiring Allergan for $63 billion in 2019, AbbVie said it’s “tracking well” against the financial commitment the company made when striking the deal. Chief Financial Officer Rob Michael said at the 2022 J.P. Morgan Healthcare Conference the company is exceeding AbbVie’s revenue expectations in the aesthetics market, led by Botox.